Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Operating Expenses (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Operating Expenses for 3 consecutive years, with $415214.0 as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 76.38% to $415214.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.3 million through Dec 2025, up 118.9% year-over-year, with the annual reading at $18.3 million for FY2025, 118.9% up from the prior year.
  • Operating Expenses hit $415214.0 in Q4 2025 for Mangoceuticals, down from $7.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $7.6 million in Q3 2025 to a low of $415214.0 in Q4 2025.
  • Historically, Operating Expenses has averaged $3.0 million across 3 years, with a median of $2.4 million in 2023.
  • Biggest YoY gain for Operating Expenses was 312.54% in 2025; the steepest drop was 76.38% in 2025.
  • Year by year, Operating Expenses stood at $2.7 million in 2023, then tumbled by 35.15% to $1.8 million in 2024, then tumbled by 76.38% to $415214.0 in 2025.
  • Business Quant data shows Operating Expenses for MGRX at $415214.0 in Q4 2025, $7.6 million in Q3 2025, and $5.4 million in Q2 2025.